Sakar Healthcare Ltd (SAKAR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Part of MojoOne Strategy

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Venus Remedies

Fredun Pharma

Sakar Healthcare

Lincoln Pharma.

Syncom Formul.

Ind-Swift Labs.

Themis Medicare

Bajaj Healthcare

Beta Drugs Ltd

Accent Microcell

Remus Pharma.

Why is Sakar Healthcare Ltd ?

With a growth in Net Profit of 126.27%, the company declared Outstanding results in Dec 25

The company has declared positive results for the last 5 consecutive quarters
PBT LESS OI(Q) At Rs 10.44 cr has Grown at 99.62%
ROCE(HY) Highest at 8.44%
NET SALES(Q) At Rs 70.34 cr has Grown at 62.00%

With ROCE of 7.9, it has a Very Expensive valuation with a 3.4 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -100.00%, its profits have risen by 69.3% ; the PEG ratio of the company is 0.7

High Institutional Holdings at 24.27%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Below par performance in long term as well as near term

Along with generating -100.00% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Sakar Healthcare should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sakar Healthcare for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Sakar Healthcare

73.67%

1.87

44.01%

Sensex

-8.27%

-0.32

13.49%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

19.47%

EBIT Growth (5y)

21.86%

EBIT to Interest (avg)

4.08

Debt to EBITDA (avg)

2.23

Net Debt to Equity (avg)

0.24

Sales to Capital Employed (avg)

0.53

Tax Ratio

9.70%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

24.27%

ROCE (avg)

7.81%

ROE (avg)

6.84%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.91

EV to EBIT

35.64

EV to EBITDA

21.54

EV to Capital Employed

3.35

EV to Sales

5.45

PEG Ratio

0.72

Dividend Yield

ROCE (Latest)

7.89%

ROE (Latest)

6.44%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

33What is working for the Company

PBT LESS OI(Q)

At Rs 10.44 cr has Grown at 99.62%

ROCE(HY)

Highest at 8.44%

NET SALES(Q)

At Rs 70.34 cr has Grown at 62.00%

OPERATING PROFIT TO INTEREST(Q)

Highest at 10.44 times

DEBT-EQUITY RATIO(HY)

Lowest at 0.24 times

PBDIT(Q)

Highest at Rs 18.59 cr.

PAT(Q)

Highest at Rs 10.25 cr.

EPS(Q)

Highest at Rs 4.61

-1What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Loading Valuation Snapshot...

Here's what is working for Sakar Healthcare

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 10.44 cr has Grown at 99.62%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 10.25 cr has Grown at 124.2%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly

Highest at Rs 70.34 cr and Grown

each quarter in the last five quarters

MOJO Watch

Near term sales trend is very positive

Net Sales (Rs Cr)

Net Sales - Quarterly

At Rs 70.34 cr has Grown at 62.00%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (Rs Cr)

Operating Profit to Interest - Quarterly

Highest at 10.44 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit (PBDIT) - Quarterly

Highest at Rs 18.59 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly

Highest at Rs 10.44 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

Highest at Rs 10.25 cr.

in the last five quarters

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Highest at Rs 4.61

in the last five quarters

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Debt-Equity Ratio - Half Yearly

Lowest at 0.24 times

in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio